Get the Stockscreener App
13.59
1.45%
-0.20
After Hours:
13.59
Oruka Therapeutics Inc stock is traded at $13.59, with a volume of 111.02K.
It is down -1.45% in the last 24 hours and up +21.23% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$13.79
Open:
$13.78
24h Volume:
111.02K
Relative Volume:
0.53
Market Cap:
$508.82M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.50%
1M Performance:
+21.23%
6M Performance:
+1.04%
1Y Performance:
+0.00%
1-Day Range:
$13.42
$14.07
1-Week Range:
$13.42
$14.46
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
13.59 | 516.30M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Is Oruka Therapeutics Inc. a candidate for recovery playRisk Managed Watchlist with Breakout Picks - Newser
How high can Oruka Therapeutics Inc. stock price go in 2025Free Risk Managed Intraday Trade Alerts - Newser
Real time scanner hits for Oruka Therapeutics Inc. explainedHigh Reward Investment Strategy for Beginners - Newser
What data driven models say about Oruka Therapeutics Inc.’s futurePortfolio Positioning Strategy With Timing - Newser
Leading vs lagging indicators on Oruka Therapeutics Inc. performanceWeekly Signal Report with Trend Summary - Newser
What makes Oruka Therapeutics Inc. stock price move sharplySmart Stock Forecast Using AI Algorithms - Newser
AI Trend Models Suggest Bounce for Oruka Therapeutics Inc.Confirmed Setup With Expert Accuracy Supported - metal.it
Oruka Therapeutics Inc. Tests 50 Day MA After Sharp DeclineHigh Conviction Intraday Stock Signals Detected - metal.it
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionRapid Trade Forecast Based on Indicators - Newser
Technical analysis overview for Oruka Therapeutics Inc. stockFree Reliable Alerts for Daily Stock Movers - Newser
Trend Dashboard Flags Oruka Therapeutics Inc. As Potential Swing TradeSecure Capital Picks With Upside Potential Tracked - metal.it
What institutional investors are buying Oruka Therapeutics Inc. stockAI Powered Forecasts With Proven Results - jammulinksnews.com
Is Oruka Therapeutics Inc. a growth stock or a value stockDynamic investment growth - jammulinksnews.com
What is the risk reward ratio of investing in Oruka Therapeutics Inc. stockGet professional guidance for market timing - jammulinksnews.com
What is Oruka Therapeutics Inc. company’s growth strategyGrow your wealth steadily and securely - jammulinksnews.com
What are the latest earnings results for Oruka Therapeutics Inc.High-octane financial growth - jammulinksnews.com
How does Oruka Therapeutics Inc. compare to its industry peersSky-high return potential - jammulinksnews.com
What catalysts could drive Oruka Therapeutics Inc. stock higher in 2025Maximize gains with timely market signals - jammulinksnews.com
Is it the right time to buy Oruka Therapeutics Inc. stockDiscover undervalued stocks before they soar - jammulinksnews.com
How volatile is Oruka Therapeutics Inc. stock compared to the marketDouble-digit growth - jammulinksnews.com
What analysts say about Oruka Therapeutics Inc. stockBreakthrough financial growth - PrintWeekIndia
What drives Oruka Therapeutics Inc. stock priceLightning-fast capital gains - Autocar Professional
Is Oruka Therapeutics Inc. a good long term investmentTremendous financial leverage - PrintWeekIndia
printweek> 2025> Oruka Therapeutics Inc. Stock Analysis and ForecastBreakthrough profits - PrintWeekIndia
H.C. Wainwright reiterates Buy rating on Oruka Therapeutics stock as FDA clears IND - Investing.com Canada
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation - TipRanks
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):